Africa needs to be better prepared to deal with future pandemics. That should start with a re-assessment of how countries invest in – and support – local research.
L’expertise universitaire, l’exigence journalistique
Articles sur Clinical trials
Affichage de 61 à 80 de 174 articles
The only way to know if a medical treatment actually works is with a randomized-controlled trial.
A century old therapy is being tested on patients with COVID-19.
A simple head-to-head trial would resolve this conflict once and for all.
Army physicians are turning to drugs approved for other conditions or newly developed treatments such as the antiviral Remdesivir to treat infected personnel.
Vaccine development is usually a long process. The coronavirus pandemic is forcing researchers to innovate and test potential vaccines faster than ever before.
A vaccine historically used to prevent tuberculosis is now among the contenders for a COVID-19 vaccine. So what is the BCG vaccine and why might it work against coronavirus?
Preliminary results from a US trial show remdesivir may help in treating COVID-19. But the findings haven’t been peer-reviewed, and the results from other clinical trials have shown little effect.
To refuse inclusion would prevent Africa’s researchers from being significant players in the universal fight against the virus.
More countries on the African continent must urgently get involved in clinical trials so that the data collected will accurately represent the continent at a genetic level.
PODCAST: The first episode of a new series from The Anthill focuses on precision medicine.
Recent evidence about the existence of nocebo effects has revealed that the way patients are informed about treatment side-effects is unethical.
The 2019 Nobel Prize in Economics pays tribute to randomized control trials, but can they really help us fight poverty?
Clinical trials are used to establish that medicines work. But these don’t take into account the genetic differences between us that can mean very different outcomes for different patients.
Drug companies have a job to do and so does Health Canada. When the relationship becomes murky, the public are at risk.
There is no doubt a regulated market for access to medicinal cannabis is safer, but if cannabis-based products were allowed to bypass efficacy trials, there’s a potential cost to patient safety.
Participants of clinical trials can easily communicate online, which poses a big problem for medical researchers.
Not all drug development needs to start from scratch. Sometimes researchers discover that a drug developed for one disease can be used for another. Here a cancer drug may show promise for dementia.
Asthma affects around 339 million people worldwide. A new drug promises to lower risks of asthma attack and may eventually allow patients to reduce their dependence on steroids.
A new agency and money for drugs for rare diseases are only very partial steps on the road towards what Canada really needs: a national pharmacare plan.
Les contributeurs les plus fréquents
-
Associate Professor of the Sydney Pharmacy School, University of Sydney
-
Director of the Oxford Empathy Programme, University of Oxford
-
Epidemiologist, Cochrane
-
Professor Emeritus of Health Policy and Management, York University, Emergency Physician at University Health Network, Associate Professor of Family and Community Medicine, University of Toronto
-
Distinguished Professor and Head of the Department of Pharmacy Practice, University of Connecticut
-
Professor of medicine, epidemiology & biostatistics, and philosophy, Western University
-
Professor of Immunology, RMIT University
-
Professor of Medicine, Monash University
-
Professor of Bioethics & Medicine, Sydney Health Ethics, Haematologist/BMT Physician, Royal North Shore Hospital and Director, Praxis Australia, University of Sydney
-
Senior Research Fellow, Bioethics, University of Sydney
-
Adjunct Clinical Associate Professor, AMREP Department of Medicine, Alfred Hospital, Melbourne & Senior Medical Oncologist and Palliative Care Physician, Melbourne Oncology Group, Cabrini Haematology and Oncology Centre, Wattletree Road, Malvern, Monash University
-
Head, Cancer Research Program, Monash University
-
Senior Lecturer in Medical Ethics and Law, St George's, University of London
-
Associate professor, UNSW
-
Researcher, L’Université d’Ottawa/University of Ottawa
